Trial Profile

Pharmacodynamic Effects of Low-dose Rivaroxaban in Combination With Antiplatelet Therapies in Patients With Coronary and Peripheral Artery Disease Manifestations

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Ticagrelor
Indications Coronary artery disease; Peripheral arterial disorders
Focus Pharmacodynamics

Most Recent Events

04 Jan 2022 Results assessing the assess PD profiles associated with adjunctive treatment of a vascular dose of rivaroxaban in patients with atherosclerotic disease on background of aspirin or DAPT, published in the Thrombosis and Haemostasis.
03 Nov 2020 Status changed from recruiting to completed.
05 Feb 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com